Andorra vs Bermuda: Tuberculosis patients living with HIV receiving antiretroviral therapy
Andorra
0 patients
in 2021
Bermuda
0 patients
in 2021
Andorra rank
141st
Bermuda rank
141st
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Andorra
- Bermuda
How they compare
Andorra currently reports 0 patients against 0 patients in Bermuda, a difference of 0 patients.
The two have swapped places 2 times across 14 shared years of data; in 2003 it was Bermuda ahead.
Andorra ranks 141st and Bermuda ranks 141st of 183 countries.
Across the 3 decades both report, Andorra averaged higher in 1 and Bermuda in 1.
Head to head by decade
| Decade | Andorra | Bermuda | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0 patients | 0 patients | 0 patients | — |
| 2010s | 0.1 patients | 0 patients | 0.1 patients | Andorra |
| 2020s | 0 patients | 0.5 patients | 0.5 patients | Bermuda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Andorra or Bermuda?
- Andorra, at 0 patients against 0 patients in Bermuda as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Andorra and Bermuda?
- 0 patients, with Andorra ahead.
- How many years of comparable data are there for Andorra and Bermuda?
- 14 years are reported by both, from 2003 to 2021.
- How do Andorra and Bermuda rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Andorra ranks 141st and Bermuda ranks 141st of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.